Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18311500 | 1.00 | GPR84 (0.54) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL4355774 | 0.98 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL28484309 | 0.98 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL27660481 | 0.98 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL1116089 | 0.98 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL574523 | 0.98 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL1115823 | 0.98 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL994542 | 0.98 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL1115968 | 0.98 | GPR84 (0.57) | GPR84FFAR1ACE2MAPTLCK | |
| SCHEMBL3500277 | 0.93 | CA2 (0.52) | GPR84FFAR1ACE2MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4641061-A1 | OIL-WELL METAL PIPE | NIPPON STEEL CORPORATION (JP) | 2025-10-29 | — | — | EP | claimed |
| WO-2024135464-A1 | OIL-WELL METAL PIPE | 日本製鉄株式会社 | 2024-06-27 | — | — | WO | claimed |
| EP-4641061-A1 | OIL-WELL METAL PIPE | NIPPON STEEL CORPORATION (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20240408180-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4412587-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | President And Fellows Of Harvard College (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118382429-A | Ionic liquids for drug delivery | 哈佛大学校长及研究员协会 | 2024-07-23 | — | — | CN | disclosed |
| WO-2024135464-A1 | OIL-WELL METAL PIPE | 日本製鉄株式会社 | 2024-06-27 | — | — | WO | disclosed |
| CN-116867785-A | Compounds and uses thereof | 福宏治疗公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116601158-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023059846-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022271537-A1 | COMPOSITIONS AND METHODS RELATING TO INJECTABLE MICROEMULSIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-1566412-B1 | CURABLE COMPOSITION AND METHOD FOR IMPROVING RECOVERY PROPERTIES AND CREEP PROPERTIES | KANEKA CORP (JP) | 2007-09-26 | — | — | EP | disclosed |
| EP-1832627-A2 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2007-09-12 | — | — | EP | disclosed |
| US-20060128919-A1 | Curable composition and methods for improving recovery properties and creep properties | KANEKA CORPORATION (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1566412-A1 | CURABLE COMPOSITION AND METHOD FOR IMPROVING RECOVERY PROPERTIES AND CREEP PROPERTIES | KANEKA CORPORATION (JP) | 2005-08-24 | — | — | EP | disclosed |
| EP-0226799-B1 | METHOD FOR PREPARING ETHYLENE GLYCOL AND/OR PROPYLENE GLYCOL | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-01-02 | — | — | EP | disclosed |
| US-4937393-A | Method for preparing ethylene glycol and/or propylene glycol | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1990-06-26 | — | — | US | disclosed |
| US-4915864-A | CARBOXYLIC ACID OR SALTS THEREOF AS SOLUBILIZING AGENT WETTING AGENT FOR GLASS, FIBERS, METALS | KAO CORPORATION (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0296432-A2 | Aqueous solution composition of strong alkali and nonionic surface active agent | Kao Corporation (JP) | 1988-12-28 | — | — | EP | disclosed |
| EP-0226799-A2 | Method for preparing ethylene glycol and/or propylene glycol | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408180-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | SLCO4C1, SLC47A1, ABCB11 | GPR84 4146/4885FFAR1 3646/4885ACE2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.